Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Volunteer Identification and Screening Logs – V 2.0

Posted on By

BA-BE Studies: SOP for Volunteer Identification and Screening Logs – V 2.0

Standard Operating Procedure for Volunteer Identification and Screening Logs in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/105/2025
Supersedes SOP/BA-BE/105/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define the procedure for proper identification, unique ID assignment, and documentation of volunteer screening and eligibility logs in Bioavailability/Bioequivalence (BA/BE) studies, ensuring compliance with regulatory and ethical standards.

2. Scope

This SOP is applicable to all clinical trial personnel involved in volunteer recruitment, screening, enrollment, and maintenance of subject screening documentation at the clinical site.

3. Responsibilities

  • Clinical Research Coordinator
(CRC): Assigns volunteer IDs and ensures screening logs are accurately maintained.
  • PI/Sub-Investigator: Reviews screening outcomes and confirms volunteer eligibility.
  • Data Entry Operator: Ensures electronic logs match physical documentation.
  • QA Officer: Verifies completeness and traceability during audits and inspections.
  • 4. Accountability

    The Principal Investigator is accountable for ensuring that volunteer identification and screening records are maintained accurately and securely, and that only eligible volunteers are enrolled based on validated documentation.

    5. Procedure

    5.1 Volunteer Identification and ID Assignment

    1. Upon first contact, assign a temporary screening number (e.g., SCR-105-001).
    2. If eligible post-screening, assign a permanent Volunteer ID (e.g., VOL-105-001) for use in CRFs, sample labels, etc.
    3. Enter details into Annexure-1: Volunteer Screening and ID Log.

    5.2 Screening Process Documentation

    1. Record each volunteer’s:
      • Name
      • Contact details
      • Date of screening
      • Screening status (Pass/Fail)
    2. Capture reasons for screening failure, if any (e.g., out-of-range vitals, lab abnormality).
    3. Use Annexure-2: Volunteer Screening Outcome Form for each individual.

    5.3 Updating Logs and Traceability

    1. Ensure logs are updated on the same day of the screening.
    2. All records must be signed and dated by the CRC or PI.
    3. Cross-verify paper records with digital logs weekly (Annexure-3: Log Verification Checklist).

    5.4 Record Confidentiality

    1. Store screening logs with personal identifiers in a locked file room with restricted access.
    2. Volunteer IDs used in study records must not reveal names or contact information.

    5.5 Archival

    1. At the end of study, archive all screening logs with study documentation.
    2. Maintain logs for the period defined by the sponsor/regulatory agency (typically 5 years).

    6. Abbreviations

    • BA: Bioavailability
    • BE: Bioequivalence
    • CRC: Clinical Research Coordinator
    • PI: Principal Investigator
    • ID: Identification

    7. Documents

    1. Volunteer Screening and ID Log – Annexure-1
    2. Volunteer Screening Outcome Form – Annexure-2
    3. Log Verification Checklist – Annexure-3

    8. References

    • ICH E6(R2) – Good Clinical Practice
    • Indian GCP Guidelines
    • Schedule Y – Drugs and Cosmetics Rules

    9. SOP Version

    Version: 2.0

    10. Approval Section

    Prepared By Checked By Approved By
    Signature
    Date
    Name
    Designation
    Department

    11. Annexures

    Annexure-1: Volunteer Screening and ID Log

    SCR No. VOL ID Full Name Screening Date Status Remarks
    SCR-105-001 VOL-105-001 Rajesh Kumar 12/04/2025 Passed Eligible

    Annexure-2: Volunteer Screening Outcome Form

    Volunteer Name Date of Screening Tests Performed Result Screening Status Comments
    Sunita Reddy 14/04/2025 Vitals, Labs Normal Passed Ready for dosing

    Annexure-3: Log Verification Checklist

    Date Verified By Discrepancies Found Corrective Action
    15/04/2025 QA Officer None NA

    Revision History:

    Revision Date Revision No. Details Reason Approved By
    10/01/2022 1.0 Initial Release GCP Requirement QA Head
    17/04/2025 2.0 Annexures added; electronic verification added Process Improvement QA Head
    See also  BA-BE Studies: SOP for Physical Examination Prior to Dosing - V 2.0
    BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

    Post navigation

    Previous Post: Creams: SOP for Testing Active Ingredient Content in Creams – V 2.0
    Next Post: Aerosol: SOP for Validating Weighing Balances in Aerosol Manufacturing – V 2.0

    Standard Operating Procedures V 1.0

    • Aerosols
    • Analytical Method Development
    • Bioequivalence Bioavailability Study
    • Capsule Formulation
    • Clinical Studies
    • Creams
    • Data Integrity
    • Dental Dosage Forms
    • Drug Discovery
    • Environment, Health and Safety
    • Formulation Development
    • Gels
    • Good Distribution Practice
    • Good Warehousing Practices
    • In-Process Control
    • Injectables
    • Liquid Orals
    • Liposome and Emulsion Formulations
    • Lotions
    • Lyophilized Products
    • Maintenance Dept.
    • Medical Devices
    • Metered-Dose Inhaler
    • Microbiology Testing
    • Nanoparticle Formulation
    • Nasal Spray Formulations
    • Nebulizers
    • Ocular (Eye) Dosage Forms
    • Ointments
    • Otic (Ear) Dosage Forms
    • Pharmacovigilance
    • Powder & Granules
    • Purchase Departments
    • Quality Assurance
    • Quality Control
    • Raw Material Stores
    • Regulatory Affairs
    • Tablet Manufacturing
    • Rectal Dosage Forms
    • Transdermal Patches
    • Vaginal Dosage Forms
    • Validations and Qualifications

    Read SOPs in your Language:

     - 
    Bengali
     - 
    bn
    English
     - 
    en
    Gujarati
     - 
    gu
    Hindi
     - 
    hi
    Malayalam
     - 
    ml
    Marathi
     - 
    mr
    Punjabi
     - 
    pa
    Tamil
     - 
    ta
    Telugu
     - 
    te

    NEW! Revised SOPs – V 2.0

    • Aerosols V 2.0
    • Analytical Method Development V 2.0
    • API Manufacturing V 2.0
    • BA-BE Studies V 2.0
    • Biosimilars V 2.0
    • Capsules V 2.0
    • Creams V 2.0
    • Elixers V 2.0
    • Ointments V 2.0
    • Raw Material Warehouse V 2.0
    • Tablet Manufacturing V2.0

    New Publication: A must for All.

    Copyright © 2025 SOP Guide for Pharma.

    Powered by PressBook WordPress theme

    Go to mobile version